Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight
Cristiana Boldrini, Micol Bottalico, Francesca L. Lia, Valentina Longo, Silvia Gigli · 2026
Read Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight by Cristiana Boldrini, Micol Bottalico, Francesca L. Lia, Valentina Longo, Silvia Gigli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421214.txt.
Description
Boldrini and colleagues reviewed in 2026 whether fertility treatments raise breast cancer risk. Assisted reproductive technologies use hormone drugs to stimulate egg release, and these hormones also act on breast tissue. The review drew on large cohort and case-control studies, pooled analyses, and guidelines.
Overall, the evidence did not show a real, consistent rise in breast cancer after these treatments. Comparisons against untreated infertile women were more reassuring than comparisons against the general public. Some studies found modest risk rises in subgroups, such as women with no prior pregnancy, many stimulation cycles, or inherited risk, but results clashed and numbers were small. Progesterone support looked safe across studies. Hormone stimulants raised estrogen briefly, yet large studies found no lasting rise in breast cancer rates.
Catalog record
| CREATOR | Cristiana Boldrini, Micol Bottalico, Francesca L. Lia, Valentina Longo, Silvia Gigli |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |